Analysis of the role of plasma 25‐hydroxyvitamin D levels in survival outcomes in patients from the phase III MPACT trial of metastatic pancreatic cancer

Role of glucuronidated 25-hydroxyvitamin D on colon gene expression in mice

AJP Gastrointestinal and Liver Physiology ◽

10.1152/ajpgi.00355.2019 ◽

2020 ◽

Vol 319 (2) ◽

pp. G253-G260

Author(s):

Carmen J. Reynolds ◽

Nicholas J. Koszewski ◽

Ronald L. Horst ◽

Donald C. Beitz ◽

Jesse P. Goff

Keyword(s):

Gene Expression ◽

Vitamin D ◽

Hydroxyvitamin D ◽

25 Hydroxyvitamin D

We found that 25OHD-Gluc, an endogenously produced metabolite, is delivered to the colon via bile to induce vitamin D-mediated responses in the colon.

Download Full-text

Role of Vitamin D in the Prevention of Pancreatic Cancer

Journal of Nutrition and Metabolism ◽

10.1155/2010/721365 ◽

2010 ◽

Vol 2010 ◽

pp. 1-9 ◽

Cited By ~ 7

Author(s):

Pubudu Bulathsinghala ◽

Kostas N. Syrigos ◽

Muhammad W. Saif

Keyword(s):

Pancreatic Cancer ◽

Vitamin D ◽

Dietary Intake ◽

Sun Exposure ◽

Current Treatment ◽

Treatment Modalities ◽

Hydroxyvitamin D ◽

Vitamin D Levels ◽

Advanced Stages

Pancreatic cancer is a malignancy of poor prognosis which is mostly diagnosed at advanced stages. Current treatment modalities are very limited creating great interest for novel preventive and therapeutic options. Vitamin D seems to have a protective effect against pancreatic cancer by participating in numerous proapoptotic, antiangiogenic, anti-inflammatory, prodifferentiating, and immunomodulating mechanisms. 25-hydroxyvitamin D [25(OH)D] serum concentrations are currently the best indicator of vitamin D status. There are three main sources of vitamin D: sun exposure, diet,and dietary supplements. Sun exposure has been associated with lower incidence of pancreatic cancer in ecological studies. Increased vitamin D levels seem to protect against pancreatic cancer, but caution is needed as excessive dietary intake may have opposite results. Future studies will verify the role of vitamin D in the prevention and therapy of pancreatic cancer and will lead to guidelines on adequate sun exposure and vitamin D dietary intake.

Download Full-text

Mistletoe Extract Therapy versus No Antineoplastic Therapy in Patients with Locally advanced or Metastatic Pancreatic Cancer: a Randomized Clinical Phase III Trial on Overall Survival

Annals of Oncology ◽

10.1016/s0923-7534(20)33290-7 ◽

2012 ◽

Vol 23 ◽

pp. ix237 ◽

Cited By ~ 2

Author(s):

D. Galun ◽

W. Tröger ◽

M. Reif ◽

A. Schumann ◽

N. Stankovic´ ◽

...

Keyword(s):

Pancreatic Cancer ◽

Overall Survival ◽

Antineoplastic Therapy ◽

Locally Advanced ◽

Phase Iii ◽

Metastatic Pancreatic Cancer ◽

Phase Iii Trial ◽

Mistletoe Extract ◽

Clinical Phase

Download Full-text

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

Journal of Clinical Oncology ◽

10.1200/jco.2006.09.0886 ◽

2007 ◽

Vol 25 (16) ◽

pp. 2212-2217 ◽

Cited By ~ 394

Author(s):

Richard Herrmann ◽

György Bodoky ◽

Thomas Ruhstaller ◽

Bengt Glimelius ◽

Emilio Bajetta ◽

...

Keyword(s):

Pancreatic Cancer ◽

Performance Status ◽

Single Agent ◽

Advanced Pancreatic Cancer ◽

Phase Iii ◽

Metastatic Pancreatic Cancer ◽

Karnofsky Performance Score ◽

Phase Iii Trial ◽

Good Performance Status ◽

Grade 3

PurposeThis phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabine (GemCap) versus single-agent Gem in advanced/metastatic pancreatic cancer.Patients and MethodsPatients were randomly assigned to receive GemCap (oral capecitabine 650 mg/m2twice daily on days 1 to 14 plus Gem 1,000 mg/m2by 30-minute infusion on days 1 and 8 every 3 weeks) or Gem (1,000 mg/m2by 30-minute infusion weekly for 7 weeks, followed by a 1-week break, and then weekly for 3 weeks every 4 weeks). Patients were stratified according to center, Karnofsky performance score (KPS), presence of pain, and disease extent.ResultsA total of 319 patients were enrolled between June 2001 and June 2004. Median overall survival (OS) time, the primary end point, was 8.4 and 7.2 months in the GemCap and Gem arms, respectively (P = .234). Post hoc analysis in patients with good KPS (score of 90 to 100) showed a significant prolongation of median OS time in the GemCap arm compared with the Gem arm (10.1 v 7.4 months, respectively; P = .014). The overall frequency of grade 3 or 4 adverse events was similar in each arm. Neutropenia was the most frequent grade 3 or 4 adverse event in both arms.ConclusionGemCap failed to improve OS at a statistically significant level compared with standard Gem treatment. The safety of GemCap and Gem was similar. In the subgroup of patients with good performance status, median OS was improved significantly. GemCap is a practical regimen that may be considered as an alternative to single-agent Gem for the treatment of advanced/metastatic pancreatic cancer patients with a good performance status.

Download Full-text

The Role of Surgery in Oligo-Metastatic Pancreatic Cancer

Textbook of Pancreatic Cancer ◽

10.1007/978-3-030-53786-9_60 ◽

2021 ◽

pp. 933-940

Author(s):

Florian Gebauer ◽

Alexander Ioannis Damanakis ◽

Felix Popp ◽

Christiane Bruns

Keyword(s):

Pancreatic Cancer ◽

Metastatic Pancreatic Cancer

Download Full-text

Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study

Cancers ◽

10.3390/cancers11070939 ◽

2019 ◽

Vol 11 (7) ◽

pp. 939 ◽

Cited By ~ 1

Author(s):

Caterina Vivaldi ◽

Lorenzo Fornaro ◽

Carla Cappelli ◽

Irene Pecora ◽

Silvia Catanese ◽

...

Keyword(s):

Pancreatic Cancer ◽

Progression Free Survival ◽

Metastatic Pancreatic Cancer ◽

Tumor Shrinkage ◽

First Line ◽

Free Survival ◽

Depth Of Response ◽

Early Tumor Shrinkage ◽

Early Tumor

Early tumor shrinkage (ETS) and depth of response (DoR) predict favorable outcomes in metastatic colorectal cancer. We aim to evaluate their prognostic role in metastatic pancreatic cancer (PC) patients treated with first-line modified-FOLFIRINOX (FOLFOXIRI) or Gemcitabine + Nab-paclitaxel (GemNab). Hence, 138 patients were tested for ETS, defined as a ≥20% reduction in the sum of target lesions’ longest diameters (SLD) after 6–8 weeks from baseline, and DoR, i.e., the maximum percentage shrinkage in the SLD from baseline. Association of ETS and DoR with progression-free survival (PFS) and overall survival (OS) was assessed. ETS was reached in 49 patients (39.5% in the FOLFOXIRI, 29.8% in the GemNab group; p = 0.280). In the overall population, ETS was significantly associated with better PFS (8.0 vs. 4.8 months, p < 0.001) and OS (13.2 vs. 9.7 months, p = 0.001). Median DoR was −27.5% (−29.4% with FOLFOXIRI and −21.4% with GemNab, p = 0.016): DoR was significantly associated with better PFS (9.0 vs. 6.7 months, p < 0.001) and OS (14.3 vs. 11.1 months, p = 0.031). Multivariate analysis confirmed both ETS and DoR are independently associated with PFS and OS. In conclusion, our study added evidence on the role of ETS and DoR in the prediction of outcome of PC patients treated with first-line combination chemotherapy.

Download Full-text